VIDEO: Evaluating CAR T-cell therapies in earlier lines of treatment

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We are currently evaluating CAR T-cell therapies in earlier lines of treatment. Either as part of initial therapy for transplant-ineligible or deferred patients in randomized phase three studies. Or there are even clinical trials trying to compare autologous stem cell transplant to CAR T-cell therapy in the front-line strategy and seeing which one is better. So, the first trial is called CAR-T25; the second one is called CAR-T26. We also have clinical trials that are in the U.S. as well as European cooperative group mechanisms, trying to piggyback off of autologous stem cell transplants and seeing if CAR Ts, can be utilized as consolidation in either high-risk patients or suboptimal responders. All of these strategies are in the clinical trial domain right now, but asking the same question —  can we make use of CAR Ts in the front-line strategy and improve survival outcome of patients?